Table 5:

Clinical outcomes of interest during the 1-year follow-up period

Outcome	Patients with ILD (N=41)
Mortality
Alive (N, %)	17 (41.5)
Deaths (N, %)	23 (56.1)
Death related to cancer	16 (39.0)
Death due to respiratory failure secondary to ILD or pneumonitis	3 (7.3)
Death due to other causes not related to ILD or cancer*	4 (9.8)
Lost to follow-up (N, %)	1 (2.4)
Hospital admission due to respiratory cause (N, %)	11 (26.8)
Due to underlying ILD or drug-induced pneumonitis	3 (7.3)
Related to other cause**	8 (19.5)
Drug-induced pneumonitis (N, %)
Attributable to immunotherapy	3 (7.3)
Attributable to chemotherapy***	1 (2.4)

^*Other causes included stroke, dementia, sepsis and gastrointestinal bleeding.

^**Other causes included COPD exacerbation and pneumonia.

^***Chemotherapy received was docetaxel.